• 1
    Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007; 99: 1695-1705.
  • 2
    Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004; 96: 218-228.
  • 3
    Nattinger AB, Laud PW, Sparapani RA, Zhang X, Neuner JM, Gilligan MA. Exploring the surgeon volume outcome relationship among women with breast cancer. Arch Intern Med. 2007; 167: 1958-1963.
  • 4
    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351: 1451-1467.
  • 5
    National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr. 2001; 30: 5-15.
  • 6
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 7
    Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23: 619-629.
  • 8
    Carlson RW, Hudis CA, Pritchard KI. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006; 4: 971-979.
  • 9
    Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
  • 10
    HewittME, GreenfieldS, StovallE, eds. From Cancer Patient to Cancer Survivor: Lost in Translation. Committee on Cancer Survivorship: Improving Quality Care and Quality of Life, National Cancer Policy Board. Washington, DC: National Academies Press; 2006.
  • 11
    Bigby J, Holmes MD. Disparities across the breast cancer continuum. Cancer Causes Control. 2005; 16: 35-44.
  • 12
    Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94: 490-496.
  • 13
    Byers TE, Wolf HJ, Bauer KR, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2008; 113: 582-591.
  • 14
    Peek ME, Han JH. Disparities in screening mammography. Current status, interventions and implications. J Gen Intern Med. 2004; 19: 184-194.
  • 15
    Downing A, Prakash K, Gilthorpe MS, Mikeljevic JS, Forman D. Socioeconomic background in relation to stage at diagnosis, treatment and survival in women with breast cancer. Br J Cancer. 2007; 96: 836-840.
  • 16
    Eaker S, Halmin M, Bellocco R, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer. 2009; 124: 180-187.
  • 17
    Buzdar A, Macahilig C. How rapidly do oncologists respond to clinical trial data? Oncologist. 2005; 10: 15-21.
  • 18
    Aiello EJ, Buist DS, Wagner EH, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008; 107: 397-403.
  • 19
    Chlebowski RT. Clinical trial presentations, agency guidelines, and oncology practice: findings from the Arimidex, Tamoxifen, Alone or in Combination trial. Clin Breast Cancer. 2008; 8: 343-346.
  • 20
    Yen TW, Fan X, Sparapani R, Laud PW, Walker AP, Nattinger AB. A contemporary, population-based study of lymphedema risk factors in older women with breast cancer. Ann Surg Oncol. 2009; 16: 979-988.
  • 21
    Nattinger AB, Pezzin LE, Sparapani RA, Neuner JM, King TK, Laud PW. Heightened attention to medical privacy: challenges for unbiased sample recruitment, and 1 solution [published online ahead of print July 21, 2010]. Am J Epidemiol. 2010.
  • 22
    Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004; 39( 6 pt 1): 1733-1749.
  • 23
    Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
  • 24
    National Cancer Institute, Surveillance Epidemiology and End Results Program. SEER Summary Staging Manual—2000. accessed January 27, 2009.
  • 25
    The North American Association of Central Cancer Registries (NAACCR), Inc. NACCR Epidemiologic Reports. Accessed January 27, 2009.
  • 26
    National Comprehensive Cancer Network (NCCN). ASCO/NCCN Quality Measures: Breast and Colorectal Cancer. Accessed January 27, 2009.
  • 27
    Sherbourne CD, Stewart AL. The MOS Social Support Survey. Soc Sci Med. 1991; 32: 705-714.
  • 28
    RAND Health. Medical Outcomes Study: Social Support Survey. socialsupport.html. Accessed January 27, 2009.
  • 29
    Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Eur J Cancer. 2002; 38: 1984-1986.
  • 30
    Svahn TH, Niland JC, Carlson RW, et al. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. J Natl Compr Canc Netw. 2009; 7: 115-121.
  • 31
    Lazovich D, Solomon CC, Thomas DB, Moe RE, White E. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 1999; 86: 628-637.
  • 32
    Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992; 326: 1102-1107.
  • 33
    Baicker K, Chandra A, Skinner JS. Geographic variation in health care and the problem of measuring racial disparities. Perspect Biol Med. 2005; 48( 1 suppl): S42-S53.
  • 34
    Baicker K, Chandra A, Skinner JS, Wennberg JE. Who you are and where you live: how race and geography affect the treatment of Medicare beneficiaries [serial online]. Health Aff (Millwood). 2004;(suppl web exclusives): VAR33-VAR44.
  • 35
    Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992; 326: 1097-1101.
  • 36
    Guadagnoli E, Weeks JC, Shapiro CL, Gurwitz JH, Borbas C, Soumerai SB. Use of breast-conserving surgery for treatment of stage I and stage II breast cancer. J Clin Oncol. 1998; 16: 101-106.
  • 37
    Pezzin LE, O'Niel MB, Nattinger AB. The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med. 2009; 24( suppl 2): S446-S450.
  • 38
    Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early stage breast cancer: 1987-2000. J Clin Oncol. 2006; 24: 872-877.
  • 39
    Silliman RA, Guadagnoli E, Rakowski W, et al. Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol. 2002; 20: 2680-2688.
  • 40
    Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002; 20: 1809-1817.
  • 41
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006; 36: 7-15.